🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We have become aware that following our communication on positive FDA feedback on Friday a statement was published that we had closed a financing transaction. To be clear, this is a LIE published by a person or group trying to drive down the stock price of MYNZ. We have not

At Mainz Biomed (NASDAQ: MYNZ), we are dedicated to delivering on key milestones. Our strong clinical results and expanding pipeline highlight our potential; however, management believes the Company’s current stock price does not adequately reflect its true value. While we cannot

"Rising demand for enhanced ColoAlert! Through Ganzimmun's trusted partnership with GANZIMMUN Diagnostics, we’re delivering faster, more reliable colorectal cancer screening. Join Ganzimmun at the 57th Medizinische Woche Baden-Baden!" Read the full press release:

Mid-Year Update from Mainz Biomed: ◾4% revenue growth, 32% decrease in operating losses. ◾Groundbreaking eAArly DETECT study presented at Digestive Disease Week 2024 shows 97% CRC sensitivity. ◾Enhanced ColoAlert® delivers faster, more accurate results. ▪️ Strategic Plans

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets Learn more : mainzbiomed.com/mainz-biomed-a… $TMO  $MYNZ #StockMaketNews #Nasdaq  #GrowthStock #Biotech #undervalued

$MYNZ Mainz Biomed announces a stock split effective Dec. 3, 2024, to increase market price, meet Nasdaq standards, and enhance investor appeal. Read the full press release: mainzbiomed.com/mainz-biomed-a… #StockMarketNews #StockMarketToday #StockUpdate #stocksplit #investor

Mainz Biomed partners with Quest Diagnostics for clinical trials of its FDA-validation colorectal cancer test. Learn more: mainzbiomed.com/mainz-biomed-f… $MYNZ $DGX #StockMarket #StockMarketUpdate #Investors #Investoropportunity #FDA #GrowthStock #Biomed

Mainz Biomed initiates the eAArly DETECT 2 U.S. study to evaluate its next-gen test for advanced adenomas in 2,000 average-risk patients. Enrollment ends mid-2025, with results expected in Q4 2025. Learn more: mainzbiomed.com/mainz-biomed-i… $MYNZ #StockMarket #StockAlert #GrowthStock

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements  Learn more: mainzbiomed.com/mainz-biomed-n… #StockMarkets #investing #growthstock #Growth #investor #investoropportunity #NASDAQ #CancerResearch $MYNZ

Preventing one of the deadliest preventable cancers! In partnership with GANZIMMUN Diagnostics, our enhanced ColoAlert test is now available across Germany for early detection. Learn more: mainzbiomed.com/mainz-biomed-a… $MYNZ #StockMarket #investoropportunity #Investor #Innovation

Saving lives through early detection! 🇨🇭 Mainz Biomed partners with Labor Team W AG to introduce ColoAlert®—a non-invasive, DNA-based colorectal cancer screening test— in Switzerland. Early detection saves lives. Easier screening = More lives saved. Learn more :

This March, we stand against colorectal cancer. Early detection saves lives. With accessible at-home testing, we help more people get tested — because every life is worth protecting. Learn more: mainzbiomed.com/colorectal-can… #Cancer #CancerAwareness #cancerai #Science #innovation

Mainz Biomed & Liquid Biosciences announce groundbreaking discovery of mRNA biomarkers for blood-based detection of #pancreatic cancer. 🧪Discovery analysis:  95% sensitivity AND 98% specificity 📄 Mainz Biomed signs exclusive license & option agreement for the biomarker

Mainz Biomed enrolls the first patient in its eAArly DETECT 2 study. 🔬 2,000+ average-risk patients ✅ Validates previous results 🛡️ Aims to shift from CRC screening to prevention 🇺🇸 Supports future U.S. programs 📅 Top-line results expected Q4 2025 Learn more:

Mainz Biomed 2024 Highlights 📈 Lab network revenue increased by 33% year over year. 📉Operating loss decreased by 30% and net loss by 18%. 🤝 New partnerships with Thermo Fisher, Quest Diagnostics, and Liquid Biosciences 💡Key moments: 📊ASCO 2024: Key colorectal cancer data

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval Read the full update here: mainzbiomed.com/mainz-biomed-p… $MYNZ #INVESTING #NASDAQ #GROWTH

Mainz Biomed and EDX Medical have joined forces. 🤝A strategic partnership to bring advanced molecular diagnostics to the UK Learn more: mainzbiomed.com/mainz-biomed-e… #stocks #investors #stockmarkets #UnitedKingdom #CancerPrevention #Cancer #Health #Medical $Nasdaq $MYNZ

eAArly DETECT 2 Clinical Study Update 🗓️Interim read out by Summer 2025! Goal: Validate next-gen test for early colon cancer detection. 🔬 Detecting polyps & precancerous adenomas. 🗓 Top-line results: Q4 2025 🇺🇸 Potential U.S. trial: 2026 Stay tuned and learn more here:

We’ve begun the feasibility phase of PancAlert, validating a biomarker panel with 95% sensitivity and 98% specificity in partnership with Crown bioscience. This step tests assay accuracy, reproducibility, and risk stratification—key for FDA. Learn more: mainzbiomed.com/mainz-biomed-i…

Big news! Mainz Biomed secured public funding from Investitions- und Strukturbank Rheinland-Pfalz (ISB), covering 50% of costs to advance their non-invasive blood test for early pancreatic cancer detection. Learn more: mainzbiomed.com/mainz-biomed-s… #Cancer #CancerResearch